公开(公告)号：US20050100891A1

公开(公告)日：2005-05-12

申请号：US11019987

申请日：2004-12-23

Applicant: Mattias Luukkonen ,  Ashlee Moses ,  Klaus Frueh ,  Jay Nelson ,  Yolanda Bell ,  Michael Heinrich ,  Kenneth Simmen

Inventor： Mattias Luukkonen ,  Ashlee Moses ,  Klaus Frueh ,  Jay Nelson ,  Yolanda Bell ,  Michael Heinrich ,  Kenneth Simmen

IPC: G01N33/53 ,  A61K31/00 ,  A61K31/07 ,  A61K31/337 ,  A61K31/704 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  A61P31/22 ,  C12M1/00 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/68 ,  C12Q1/6837 ,  C12Q1/6883 ,  G01N21/77 ,  G01N21/78 ,  G01N33/58 ,  G01N37/00 ,  G06Q50/22 ,  C12Q1/70 ,  C12M1/34 ,  A61K38/16

CPC classification number: C12Q1/6883 ,  A61K31/00 ,  A61K31/337 ,  A61K31/704 ,  A61K38/212 ,  A61K45/06 ,  C12Q1/6837 ,  C12Q2600/158 ,  G06Q50/22 ,  Y02A90/22 ,  A61K2300/00

Abstract: The present invention utilizes nucleic acid microarray technology to identify changes in the host endothelial cell transcription pattern that occurs during the latent and lytic phase of the KSHV life cycle. The production or activity of some genes up regulated during the lytic cycle were subsequently inhibited, and two such targets were shown to have a role in expression of late viral genes. Using this combined approach we have identified cellular pathways previously unknown to be important for KSHV infection, and present evidence for the efficiency of the novel antiviral approaches thus discovered. In addition, the present invention identifies a wide variety of endothelial cells genes and pathways that are involved in a variety of endothelial cell-mediated activity, including angiogenesis and transformation.

Abstract translation: 本发明利用核酸微阵列技术鉴定在KSHV生命周期的潜伏期和裂解期期间发生的宿主内皮细胞转录模式的变化。 随后抑制溶解循环中上调的一些基因的产生或活性，并且显示出两个这样的靶点在晚期病毒基因的表达中起作用。 使用这种组合方法，我们已经确定以前未知对KSHV感染重要的细胞途径，并提供了因此发现的新型抗病毒方法的效率的证据。 此外，本发明鉴定参与多种内皮细胞介导的活性的多种内皮细胞基因和途径，包括血管生成和转化。

公开(公告)号：US20090247523A1

公开(公告)日：2009-10-01

申请号：US12443190

申请日：2007-10-04

Applicant: Pierre Jean-Marie Bernard Raboisson ,  Oliver Lenz ,  Tse-I Lin ,  Kenneth Simmen

Inventor： Pierre Jean-Marie Bernard Raboisson ,  Oliver Lenz ,  Tse-I Lin ,  Kenneth Simmen

IPC: A61K31/5377 ,  C07D401/12 ,  A61K31/506 ,  C07D413/14 ,  A61P31/12

CPC classification number: A61K31/506 ,  A61K31/535 ,  A61K2300/00

Abstract: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

Abstract translation: 本发明涉及羧酰胺4 - [（4-吡啶基）氨基] - 嘧啶作为HCV复制的抑制剂的用途，以及它们在旨在治疗或对抗HCV感染的药物组合物中的用途。

公开(公告)号：US09987277B2

公开(公告)日：2018-06-05

申请号：US12443190

申请日：2007-10-04

Applicant: Pierre Jean-Marie Bernard Raboisson ,  Oliver Lenz ,  Tse-I Lin ,  Kenneth Simmen

Inventor： Pierre Jean-Marie Bernard Raboisson ,  Oliver Lenz ,  Tse-I Lin ,  Kenneth Simmen

IPC: A61K31/21 ,  A61K31/506 ,  A61K31/535

CPC classification number: A61K31/506 ,  A61K31/535 ,  A61K2300/00

Abstract: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

公开(公告)号：US20070155716A1

公开(公告)日：2007-07-05

申请号：US11684288

申请日：2007-03-09

Applicant: Kenneth SIMMEN ,  Tse-I Lin ,  Oliver Lenz ,  Dominique Louis Surleraux ,  Pierre Jean-Marie Raboisson

Inventor： Kenneth SIMMEN ,  Tse-I Lin ,  Oliver Lenz ,  Dominique Louis Surleraux ,  Pierre Jean-Marie Raboisson

IPC: A61K31/55 ,  A61K31/519 ,  A61K31/541 ,  A61K31/5377

CPC classification number: A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  A61K31/5377 ,  Y02A50/385 ,  Y02A50/387

Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.

Abstract translation: 本发明涉及双环嘧啶作为HCV复制抑制剂的用途，以及它们在旨在治疗或对抗HCV感染的药物组合物中的用途。 此外，本发明涉及这种药物组合物的制备方法。 本发明还涉及本发明的双环嘧啶与其它抗HCV药物的组合。

公开(公告)号：US20060189559A1

公开(公告)日：2006-08-24

申请号：US11305707

申请日：2005-12-16

Applicant: Ruilin Zhao ,  Lieven Baert ,  Kenneth Simmen

Inventor： Ruilin Zhao ,  Lieven Baert ,  Kenneth Simmen

IPC: A61K48/00 ,  A61K9/22

CPC classification number: A61M5/14276 ,  A61M5/14232 ,  A61M5/152 ,  A61M2210/1071

Abstract: A method and system for treating Hepatitis C includes using an implantable pump and an outlet catheter. A proximal end of the outlet catheter is fluidly connected to an outlet port of the pump. A distal end of the outlet catheter is sized to deliver medication from the pump to a liver of living organism, preferably a human being. By delivering medication directly to the liver the effects of the antiviral therapeutics are enhanced, and the impact of Hepatitis C infection is reduced.

Abstract translation: 用于治疗丙型肝炎的方法和系统包括使用可植入泵和出口导管。 出口导管的近端流体地连接到泵的出口。 出口导管的远端的尺寸被设计成将药物从泵输送到生物体的肝脏，优选人。 通过直接向肝脏输送药物，可以增强抗病毒药物的作用，降低丙型肝炎感染的影响。